Virpax Pharmaceuticals, Inc.

NasdaqCM:VRPX Stock Report

Market Cap: US$4.9m

Virpax Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Virpax Pharmaceuticalshan disminuido a un ritmo medio anual de -41.8%, mientras que en el sector Pharmaceuticals los beneficios se situaron en growing a un ritmo anual de 6.5%.

Key information

-37.5%

Earnings growth rate

-5.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equity-785.3%
Net Marginn/a
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

Virpax Pharmaceuticals GAAP EPS of -$0.50 misses by $0.06

Aug 15

Virpax: Targeting Pain At Its Source

Sep 04

Virpax Pharmaceuticals shares surge on Envelta IND update

Jun 21

Revenue & Expenses Breakdown
Beta

How Virpax Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:VRPX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-1585
30 Sep 230-1487
30 Jun 230-1588
31 Mar 230-1889
31 Dec 220-2299
30 Sep 220-231210
30 Jun 220-1889
31 Mar 220-1587
31 Dec 210-1275
30 Sep 210-953
30 Jun 210-752
31 Mar 210-642
31 Dec 200-431
30 Sep 200-431
30 Jun 200-431
31 Mar 200-321
31 Dec 190-331

Beneficios de calidad: VRPX actualmente no es rentable.

Creciente margen de beneficios: VRPX actualmente no es rentable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Tendencia de beneficios: VRPX no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 41.8% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de VRPX en el último año con su media de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: VRPX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Pharmaceuticals (-3.2%).


Return on Equity

Alto ROE: VRPX tiene un Rendimiento de los fondos propios negativo (-209.28%), ya que actualmente no es rentable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.